INSERM, UMR 1027, Toulouse, France.
Toulouse III University, Toulouse, France.
HIV Med. 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441. Epub 2016 Oct 7.
The aim of the study was to describe the ageing HIV-infected population (> 50 years old) and their current antiretroviral therapy (ART), comorbidities and coprescriptions in France in 2013 and to compare them to the younger population.
A retrospective analysis of a prospectively collected database was performed. The characteristics of patients receiving ART as well as their current ART and their numbers of comorbidities and comedications at the censoring date (1 July 2013) were compared between patients ageing with HIV infection, patients who seroconverted while ageing, and younger patients.
We compared 10 318 ageing patients [median age 56 years; 25% interquartile range (IQR) 53-62 years] with 13 302 younger patients (median age 42 years; 25% IQR 36-47 years). The ageing patients were more frequently male than the younger patients (77 vs. 65%). Among the ageing patients, 7025 were diagnosed with HIV infection before 2000 and represented a distinct group, the 'experienced ageing' group, by comparison with the 'recently diagnosed ageing' group. Triple therapy containing a boosted protease inhibitor was used in 28.2% of the patients (vs. 39% and 36% of the younger and "recently diagnosed ageing" groups, respectively); a nonnucleoside reverse transcriptase inhibitor in 27% (vs. 33% and 38%, respectively), an integrase strand transfer inhibitor (INSTI) in 9% (vs. 7% and 9%, respectively), and another regimen (fewer or more than three drugs) in 35.8% (vs. 21% and 16.5%, respectively). "Experienced ageing" patients typically had one or more comorbidities (62.1%) and were receiving at least one comedication (71%). Central nervous system (CNS) agents (prescribed in 44.6% of the "experienced ageing" patients) and antilipidaemics (in 44.2%) were the most frequently prescribed comedications. INSTIs were used in 23% of the population and were used significantly more often in patients with comorbidities and coprescriptions. For all comparisons, P < 0.0001.
In ageing HIV-infected patients, especially those with a long history of HIV infection, comorbidities and coprescriptions are highly prevalent.
本研究旨在描述法国 2013 年年龄大于 50 岁的 HIV 感染者人群及其当前的抗逆转录病毒治疗（ART）、合并症和合并用药情况，并与年轻人群进行比较。
回顾性分析前瞻性收集的数据库。比较年龄增长的 HIV 感染者、年龄增长时发生 HIV 血清转换的患者和年轻患者在截止日期（2013 年 7 月 1 日）时接受 ART 的患者特征、当前 ART 和合并症及合并用药数量。
我们比较了 10318 例年龄增长的患者[中位年龄 56 岁；25%四分位间距（IQR）53-62 岁]和 13302 例年轻患者（中位年龄 42 岁；25% IQR 36-47 岁）。与年轻患者相比，年龄增长的患者中男性更为常见（77% vs. 65%）。在年龄增长的患者中，7025 例患者在 2000 年之前被诊断为 HIV 感染，与“近期诊断的年龄增长”组相比，他们构成了一个独特的群体，即“有经验的年龄增长”组。含强化蛋白酶抑制剂的三联疗法在 28.2%的患者中使用（分别为年轻患者和“近期诊断的年龄增长”组的 39%和 36%）；27%的患者使用非核苷类逆转录酶抑制剂（分别为 33%和 38%）；9%的患者使用整合酶抑制剂（INSTI）（分别为 7%和 9%），35.8%的患者使用其他方案（少于或多于三种药物）（分别为 21%和 16.5%）。“有经验的年龄增长”患者通常有 1 种或多种合并症（62.1%），至少接受 1 种合并用药（71%）。中枢神经系统（CNS）药物（44.6%的“有经验的年龄增长”患者使用）和降脂药（44.2%）是最常使用的合并用药。INSTI 在人群中使用 23%，在有合并症和合并用药的患者中使用更为频繁。所有比较中，P<0.0001。
在年龄增长的 HIV 感染者中，尤其是那些 HIV 感染史较长的患者，合并症和合并用药非常普遍。
